Tiziana Reports Phase 1 Clinical Data Demonstrating Nasal Treatment with Foralumab was Welltolerated and Produced Positive Trend in Biomarkers of Immunomodulation and Antiinflammation in Healthy Volunteers

THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION 5962014. UPON PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE THIS INFORMATION ...